Effects of Dihydropyridine Calcium Channel Inhibitors on Respiratory Gas Exchanges in the Intensive Care Unit: a Pharmacovigilance Study in VigiBase® and a Comparison With Urapidil

Caen University Hospital

Status: Completed

Conditions: Hypoxia

Treatments: Drug: dihydropyridine calcium channel inhibitors use

Study type: Observational

Funder types: Other

Identifiers

NCT05537194

Pharmaco 20220908

Details and patient eligibility

About

Due to their effects on hypoxic pulmonary vasoconstriction (HPV), dihydropyridine calcium channel inhibitors (CCI) could lead to hypoxia in patients with a pulmonary shunt. To the present time only preclinical studies and case reports focused on this potential adverse drug reaction. We aimed to assess the reporting association between CCI and hypoxia using the World Health Organization pharmacovigilance database (VigiBase®).

Enrollment: 32,000,000 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• present in the database

Exclusion criteria

• chronology not compatible with the drug imputability

Trial design

32,000,000 participants in 2 patient groups

Patients with hypoxia

Treatment:

Drug: dihydropyridine calcium channel inhibitors use

Patients without hypoxia

Treatment:

Drug: dihydropyridine calcium channel inhibitors use